NCT01739530 is a Phase 1 clinical trial of Repaircell in Healthy, sponsored by Anterogen Co., Ltd..

Who is sponsoring NCT01739530?

NCT01739530 is sponsored by Anterogen Co., Ltd..

What drugs are being tested in NCT01739530?

Interventions in NCT01739530: Repaircell.

Is NCT01739530 still recruiting?

NCT01739530 is currently completed. Last updated 3 December 2012.

Last reviewed 2012-12-03 · How we verify

NCT01739530

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I Study to Evaluate Safety of Repaircell in Healthy Volunteers

Completed Phase 1 Last updated 3 December 2012

What this trial tests

Phase 1 trial testing Repaircell in Healthy in 5 participants. Completed in 1 December 2009.

Timeline

1 March 2009

Primary endpoint
1 November 2009

1 December 2009

Quick facts

Lead sponsor	Anterogen Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	5
Start date	1 March 2009
Primary completion	1 November 2009
Estimated completion	1 December 2009
Sites	1 location across South Korea

Drugs / interventions tested

Repaircell — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Anterogen Co., Ltd. — full company profile →

Who can join

19 and older, male only, with Healthy. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Adverse events
Time frame: week 8
Evaluate the safety at week 8 whether any kind of Adverse event occurs

Sponsor's own description

Allogenic differentiated adipocytes (ANT-adip-AL) is produced by well-established techniques including cell harvesting from lipoaspirates obtained from healthy donors, expansion of adipose tissue derived stem cells, and differentiation into pure and immature adipocytes. This was an open-label study. Subjects were received subcutaneous injection of ANT-adip-AL and followed for 8 weeks according to the clinical trial protocol.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Adipose-Derived Stem Cells for Tissue Engineering and Regenerative Medicine Applications.
Dai R, Wang Z, Samanipour R, Koo KI, et al · · 2016 · cited 191× · PMID 27057174 · DOI 10.1155/2016/6737345
Clinical implication of allogenic implantation of adipogenic differentiated adipose-derived stem cells.
Kim I, Bang SI, Lee SK, Park SY, et al · · 2014 · cited 31× · PMID 25273542 · DOI 10.5966/sctm.2014-0109

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Anterogen Co., Ltd. trials

Trials by the same sponsor.

NCT06539429 — Clinical Study to Evaluate Efficacy and Safety of ANT-301 in Patients With Knee Osteoarthritis in Grade III/IV by K/L · Phase 1 · active not recruiting
NCT05157958 — Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa · Phase 2 · recruiting
NCT06141811 — A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-302 Clinical Trial · recruiting
NCT04569409 — Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers. · Phase 3 · completed
NCT04590703 — A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-301 Clinical Trial · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01739530 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Anterogen Co., Ltd.
Last refreshed: 3 December 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01739530.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing